Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
THEO-DUR vs AEROLATE JR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits phosphodiesterase, increasing c AMP levels; antagonizes adenosine receptors; enhances contractility of skeletal and cardiac muscle, and relaxes bronchial smooth muscle.
Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.
Treatment of asthma and chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, such as emphysema and chronic bronchitis.
300-600 mg orally twice daily
1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.
Terminal elimination half-life: 3-9 hours in adults (smokers: 4-5 hours; nonsmokers: 6-9 hours); 20-30 hours in premature neonates; 1-5 hours in children. Prolonged in hepatic cirrhosis, heart failure, and with CYP1A2 inhibitors.
Terminal elimination half-life: 3.5-4.5 hours. This short half-life supports twice-daily dosing in asthma management, with trough levels remaining above therapeutic threshold.
Primarily hepatic via CYP1A2 and CYP3A4; also by N-acetylation and CYP2E1.
Primarily metabolized in the liver by cytochrome P450 enzymes, including CYP1A2, CYP2E1, and CYP3A4. Metabolism is saturable at high concentrations.
Primarily hepatic metabolism by CYP1A2 and CYP3A4; renal excretion of unchanged drug accounts for approximately 10% in adults, up to 50% in neonates; biliary/fecal excretion negligible.
Renal elimination: 60-70% as unchanged drug and metabolites. Biliary/fecal excretion: 20-30%.
Approximately 40-60% bound primarily to albumin. Lower in neonates, cirrhotics, and uremic patients.
Approximately 70% bound to plasma proteins, primarily albumin.
Vd: 0.3-0.7 L/kg. Distributes into total body water; higher Vd in neonates (0.6-0.8 L/kg) and with acidosis.
Volume of distribution: 0.3-0.5 L/kg. This moderate Vd indicates distribution into total body water and some tissue binding, but limited by protein binding.
Oral: nearly 100% for immediate-release; extended-release formulations have 90-100% relative bioavailability compared to immediate-release.
Oral bioavailability: Approximately 50% due to first-pass metabolism. Inhalation bioavailability: Variable, with 10-20% reaching systemic circulation; remainder swallowed and undergoes first-pass metabolism.
GFR 10-50 m L/min: reduce dose by 25%; GFR <10 m L/min: reduce dose by 50%
No adjustment required as drug is primarily hepatically metabolized.
Child-Pugh A: reduce dose by 50%; Child-Pugh B or C: reduce dose by 75-80%
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended.
Initial: 10-20 mg/kg/day orally divided q12h; titrate based on serum levels (therapeutic range 5-15 mcg/m L)
Children 4-11 years: 1 inhalation (35 mcg) twice daily; children 12-17 years: same as adult.
Start at lowest effective dose; monitor serum levels; decrease dose by 25-50% due to reduced clearance
No specific dose adjustment; initiate at lower end of dosing range due to potential comorbidities.
No
None.
Risk of serious or fatal cardiovascular adverse events, including seizures and arrhythmias, especially at high doses.,Use with caution in patients with peptic ulcer, seizure disorders, cardiac disease, or hepatic impairment.,Monitor serum theophylline levels to avoid toxicity.,May exacerbate GERD.
Concurrent illness (especially with fever), smoking cessation, drug interactions, and hepatic or cardiac impairment can significantly alter theophylline clearance. Serum levels must be monitored due to narrow therapeutic index. Use with caution in patients with peptic ulcer, seizure disorders, or hyperthyroidism.
Hypersensitivity to theophylline or any component of the formulation.,Concurrent use with ticlopidine or cimetidine (due to significant drug interactions)
Hypersensitivity to theophylline or any component of the formulation.
Food does not significantly affect absorption of sustained-release formulations; however, high-fat meals may slow absorption. Avoid large amounts of caffeine-containing foods/beverages. Charcoal-broiled foods may increase metabolism.
High-fat meals may delay absorption. Charcoal-broiled foods and high-protein diets can increase clearance. Avoid concurrent consumption of large amounts of caffeine.
Theophylline (THEO-DUR) is not known to be a major human teratogen. First trimester: limited data show no consistent increase in major malformations; however, case reports suggest a possible association with cardiovascular defects and oral clefts, though risk is low. Second and third trimesters: chronic high doses may cause fetal tachycardia and irritability; no structural teratogenicity reported. Overall, FDA Pregnancy Category C; risk vs benefit must be considered.
FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used near term due to beta-agonist effects; avoid for tocolysis.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Infant exposure via milk is about 1-10% of maternal weight-adjusted dose. May cause irritability or insomnia in neonates. Use with caution, and monitor infant for signs of theophylline toxicity. Breastfeeding is generally considered acceptable if maternal levels are within therapeutic range and infant is observed.
Excreted in breast milk; M/P ratio 2.5. Use caution; may cause tremors or tachycardia in infant. Consider risk-benefit.
Pregnancy increases theophylline clearance by approximately 30-50% due to hemodilution and increased hepatic metabolism. Dose may need to be increased by 30-50% to maintain therapeutic levels. Monitor serum concentrations frequently (every 1-2 weeks) and adjust accordingly. After delivery, clearance returns to prepregnancy levels within 2-4 weeks, requiring dose reduction to avoid toxicity.
Pregnancy may reduce plasma concentrations due to increased clearance; consider dose adjustment based on clinical response. Monitor for hypokalemia.
Theo-Dur (theophylline) has a narrow therapeutic index; target serum concentration is 5-15 mcg/m L. Levels >20 mcg/m L increase toxicity risk. Monitor levels, especially with hepatic impairment, heart failure, or drugs that alter CYP1A2 metabolism (e.g., cimetidine, fluoroquinolones). Avoid use in active seizure disorders unless controlled. Use with caution in peptic ulcer disease.
AEROLATE JR (theophylline) is a bronchodilator used for asthma and COPD. Due to narrow therapeutic index, monitor serum levels (target 5-15 mcg/m L). Caffeine and smoking affect metabolism; smoking cessation may require dose reduction. Avoid in seizure disorders or peptic ulcer.
Take exactly as prescribed; do not change dose or stop without consulting doctor.,Do not crush or chew sustained-release tablets; swallow whole.,Avoid excessive caffeine intake (coffee, tea, chocolate) as it may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, palpitations, seizures.,Keep regular appointments for blood level monitoring.
Take exactly as prescribed; do not change dose without consulting doctor.,Avoid excessive caffeine (coffee, tea, soda, chocolate) as it may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, seizures.,Do not smoke or abruptly stop smoking; notify doctor if smoking habits change.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about THEO-DUR vs AEROLATE JR, answered by our medical review team.
THEO-DUR is a Bronchodilator that works by Inhibits phosphodiesterase, increasing c AMP levels; antagonizes adenosine receptors; enhances contractility of skeletal and cardiac muscle, and relaxes bronchial smooth muscle.. AEROLATE JR is a Bronchodilator that works by Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between THEO-DUR and AEROLATE JR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of THEO-DUR is: 300-600 mg orally twice daily. The standard adult dose of AEROLATE JR is: 1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between THEO-DUR and AEROLATE JR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. THEO-DUR is classified as Category C. Theophylline (THEO-DUR) is not known to be a major human teratogen. First trimester: limited data show no consistent increase in major malformations; however, case reports suggest . AEROLATE JR is classified as Category C. FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used nea. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.